We demonstrated in primary JMML cell cultures that knockdown of overexpressed lncRNAs such as lnc-THADA-4, lnc-ACOT9-1 and NRIR may be a feasible therapeutic strategy. The gene discussed is ACOT9; the disease is juvenile myelomonocytic leukemia.